Compare Adaptive Biotechnologies Corp (ADPT) vs Suncor Energy Inc. (SU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Suncor Energy Inc. — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Suncor Energy Inc. trades at $59.01 (market cap $66.94B). The key difference: Suncor Energy Inc. is far larger — about 20.1× Adaptive Biotechnologies Corp's market cap, and Suncor Energy Inc. pays a 2.98% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | SU | |
|---|---|---|
Market Cap | $3.33B | $66.94B |
Sector | Health | Energy |
52-Week High | $22.37 | $69.73 |
52-Week Low | $10.24 | $38.17 |
Enterprise Value | $3.19B | $75.07B |
Dividend Yield | — | 2.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Suncor Energy (SU) trades at $56.66, up 2.92% today, with a bullish technical signal despite mixed moving averages. The stock shows solid fundamentals with a P/E of 14.82, net margin of 11.62%, and consistent dividend payments, including a recent $0.60 distribution. Recent earnings beat expectations in Q3 and Q4 2025, though Q1 2026 missed estimates. Analyst consensus is strongly positive with 74% buy ratings.
Outlook remains favorable due to attractive valuation and strong cash flow, but risks include oil price volatility and operational incidents like the recent Sarnia refinery fire. Earnings growth and disciplined capital allocation are key catalysts for upside, while macroeconomic pressures pose headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Suncor Energy Inc.
Suncor Energy Inc is an integrated energy company. The company's operations include oil sands development, production and upgrading, offshore oil and gas, petroleum refining in Canada and the U.S. and the company's PetroCanada retail and wholesale distribution networks. The company is developing petroleum resources while advancing the transition to a low-emissions future through investment in power, renewable fuels and hydrogen. It also conducts energy trading activities focused principally on the marketing and trading of crude oil, natural gas, byproducts, refined products and power.
Read more on SU →
